Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX038 in Advanced Solid Tumors
NCT02646852Phase 1Completed
- Sponsor
- ProLynx Inc.
- Start
- Mar 2016
- Primary completion
- Feb 2023
- Modality
- Polymer-based Nanoparticles, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PLX038 in solid tumor (2 arms), sponsored by ProLynx Inc. Primary endpoint: Number of patients with adverse events. Started Mar 2016; status: completed.
02
Drugs
PLX038
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02646852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02646852.